Avid Bioservices Inc (CDMO)

[Fire Fox]

FTM-- Thanks for getting out this summary chart so quickly-- it's the picture that is worth ten thousand words. Today the BPs with whom we are talking partnership are looking at the data in this chart, not at the pps.

Could you please help me confirm an important point that appears to make Bavi results today even stronger. In you post #110144 your chart reports that in the Bavi 3mg arm 24.4% of the patients were ECOG PS 2. Where did you get that number? Was it based on all 40 patients as reported back in Sept.? Is it still a valid number today?

ECOG PS 2 patients are MUCH sicker than the PS 0 and 1 patients.

Everyone should review FTM's chart in post 110144 and notice that the 3 other trials reporting treatment arm MOS greater than 10 months (i.e. Herbst in 2010, Pallis in 2010 and Ramlau in 2012) had PS 2 populations of only 1%, 11.9% and 4.6% respectively.

BPs will surely notice that Bavi achieved MOS of 11.7 months in a patient population having twice as many very sick PS 2 patients.